Merck: Gefapixant Significantly Reduced Cough Frequency Compared To Placebo In Two Phase 3 Trials

Merck & Co. Inc. (MRK) on Tuesday announced the results from two pivotal Phase 3 trials, COUGH-1 and COUGH-2, evaluating the efficacy and safety of gefapixant (MK-7264) for the potential treatment of refractory or unexplained chronic cough.

from RTT - Biotech https://ift.tt/337S6eC
via IFTTT